Conclusions & Recommendations
16.16.1 - Pakistan
Conclusion/Recommendation:
The TEC is encouraged by the funding committed by the government for trachoma baseline mapping and encourages future investment in trachoma program implementation. ITI is ready to support the program with Zithromax® where warranted.
Action:
The TEC recommendation was shared with the MOH and the national program are working
with partners including Fred Hollows Foundation, Sightsavers, and CBM to identify funding
for mapping.
TEC 16
2017
Eastern Mediterranean
Pakistan
funding, suspected endemic
16.17.1 - Sudan
Conclusion/Recommendation:
TEC recognizes that security has prevented timely distribution in El Kormak and encourages the national program to conduct MDA when security allows.
Action:
The Sudan program is still waiting for a secure opportunity to treat this district.
TEC 16
2017
Eastern Mediterranean
Sudan
insecurity
16.18.1 - Colombia
Conclusion/Recommendation:
The TEC encourages the continued application of innovative strategies for surveys and implementation in the Colombia trachoma program, given the isolated and remote nature of its endemic populations.
Action:
The TEC recommendations were shared with the MOH.
TEC 16
2017
Americas
Colombia
special populations
16.19.1 - Vietnam
Conclusion/Recommendation:
TEC reassures the VNIO that the pocket of disease should not prevent them from submitting a dossier.
Action:
TEC recommendation was communicated to the VNIO and RTI ENVISION are supporting the
VNIO with dossier preparation.
TEC 16
2017
South East Asia
Viet Nam
end game
16.2.1 - Zithromax® for Refugee Camps
Conclusion/Recommendation:
The TEC recommends to ITI and the Refugee subcommittee to develop a working paper to reflect on experience with Zithromax® decision making in refugee and IDP settings and consider appropriate methodologies for surveys and surveillance for presentation at TEC17.
Action:
This work is in progress and will be reported during TEC 18.
TEC 16
2017
special populations, recommendations for ITI management, Zithromax® donation criteria
16.2.2 - Zithromax® for Refugee Camps
Conclusion/Recommendation:
If the Global Scientific Meeting for trachoma is held in advance of TEC17 and includes discussions on how to address trachoma in refugee and IDP settings, include a presentation at TEC17.
Action:
The GSM has not yet taken place.
TEC 16
2017
special populations
16.3.1 - Progress in the Global Programme
Conclusion/Recommendation:
The TEC celebrated that the increased funding for MDA and impact/surveillance surveys have enabled many countries to reach 100% geographic scale. Several countries have begun scale down following successful implementation of A, F, and E.
Action:
TEC 16
2017
funding
16.4.1 - Impact and Surveillance Surveys in Districts with Large Populations
Conclusion/Recommendation:
The TEC recommends that during impact and baseline surveys, districts with large populations (>250,000 people) be split into multiple evaluation units of the recommended survey size (100,000-250,000 people) that align to functional implementation units.
Action:
This is noted and being implemented by the Tropical Data partnership.
TEC 16
2017
evaluation units
16.4.2 - Impact and Surveillance Surveys in Districts with Large Populations
Conclusion/Recommendation:
The TEC will allocate drug according to the evaluation unit-specific results from the surveys; the MOH is thus encouraged to consider how best to define these evaluation units bearing in mind future MDA implementation.
Action:
TEC 16
2017
evaluation units, Zithromax® donation criteria
16.5.1 - Coverage
Conclusion/Recommendation:
The TEC recommends that at TEC17, TEC identify criteria for triggering concerns about coverage.
Action:
The ITI Data & Analytics Team analyzed the data available in the GET2020 Database and will
present their findings on this issue during TEC17.
TEC 16
2017
coverage, TEC meeting management